SEP 26 2026
AbbVie — tavapadon $ABBV
for Parkinson's disease
Accepted NOV 26 2025.
About
Parkinson's disease is a neurodegenerative disorder that causes tremors, slowed movement, stiffness, and balance problems, along with non-motor symptoms like sleep disturbances and cognitive decline. Tavapadon is a selective dopamine receptor activator that mimics natural dopamine signals in the brain. By targeting specific dopamine pathways, it may help restore motor control and ease symptoms in Parkinson's patients.
Pivotal trial
The purpose of this study is to evaluate the clinical efficacy, safety and pharmacokinetics (PK) of 2 fixed doses of tavapadon and placebo in participants with early PD.
Source: ClinicalTrials.gov
Also in development
Drug Watch — recent news on tavapadon
- How Investigational Tavapadon Changes the Parkinson Disease Treatment Landscape - Neurology Live
- Tavapadon, Dopamine Agonists, and the Expansion of Parkinson Treatment Options - Neurology Live
- New Once-Daily Parkinson’s Drug Tavapadon Nears FDA Decision - Being Patient
- Understanding Tavapadon’s Mechanism and Clinical Potential in Treating Parkinson Disease: Hubert Fernandez, MD - Neurology Live
- Understanding Levodopa Use in Patients With Parkinson’s Disease on Tavapadon - Docwire News